# US 2022/0031704 A1 · Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031704 A1
- Document ID: US20220031704A1
- Status: Published application
- Kind: A1
- Application number: 17/297,369
- Filed: 2019-11-27
- Published: 2022-02-03
- Earliest claimed: 2018-11-28
- Assignees: Topadur Pharma AG
- Applicants: Topadur Pharma AG
- Inventors: Guido KOCH; Esra LONE; Selena DI MAIO; Reto NAEF; Jeanette PETERKE; Michael SPOERRI; Hermann TENOR; Elia MARTINI
- Web page: https://patentgrep.com/patent/US20220031704A1

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/08: Vasodilators for multiple indications
- C07D 487/04: Ortho-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to compounds of formula (I) or formula (II) or pharmaceutically acceptable salt, solvate or hydrate thereof, wherein said compound of formula (I) and said compound of formula II each comprises at least one ONO2 or ONO moiety; R1 is C1-C3alkyl; R2 is H, C1-C6alkyl, C3-C6cycloalkyl, C1-C2alkoxy, C2-C4alkenyl; R3 is C1-C4alkyl optionally substituted with C1-C2alkoxy, C3-C4cycloalkyl, C2-C4alkenyl; R4 and R5 are each independently H or C1-C6alkyl optionally substituted with F, OH, ONO, ONO2, COOH, C1-C3alkoxy, C3-C6cycloalkyl; or together with the nitrogen atom to which they are attached form a heterocyclic ring, wherein preferably said heterocyclic ring is selected from aziridine, azetidine, pyrollidine, piperidine, morpholine, piperazine, homo-piperazine, 2,5-diazabicyclo[2,2,1]heptane and 3,7-diazabicyclo[3,3,0]octane, wherein said heterocyclic ring is optionally substituted with independently one or more R6; R6 is C1-C6alkyl optionally substituted with independently one or more halogen, OH, ONO, ONO2, C1-C3alkoxy, C1-C3haloalkoxy, COOR7, NR8R9, C═NR10; R7 is H, or C1-C4alkyl optionally substituted with F, OH, ONO, ONO2, NR8R9; R8 and R9 are independently H, or C1-C4alkyl optionally substituted with ONO, ONO2; R10 is C1-C4alkyl optionally substituted with F, ONO, ONO2; C3-C6cycloalkyl; pharmaceutical compositions thereof, and their use in methods of treating or preventing a disease alleviated by inhibition of PDE5 in a human or in a non-human mammal

## Claims

### Claim 1

A compound of formula I or formula II
or pharmaceutically acceptable salt, solvate or hydrate thereof, wherein
said compound of formula I and said compound of formula II each comprises at least one covalently bound ONO2 or ONO moiety;
R1 is C1-C3alkyl;
R2 is H, C1-C6alkyl, C3-C6cycloalkyl, C1-C2alkoxy, C2-C4alkenyl;
R3 is C1-C4alkyl optionally substituted with C1-C2alkoxy, C3-C4cycloalkyl, C2-C4alkenyl;
R4 and R5 are each independently H or C1-C6alkyl optionally substituted with F, OH, ONO, ONO2, COOH, C1-C3alkoxy, C3-C6cycloalkyl; or together with the nitrogen atom to which they are attached form a heterocyclic ring, wherein preferably said heterocyclic ring is selected from aziridine, azetidine, pyrollidine, piperidine, morpholine, piperazine, homo-piperazine, 2,5-diazabicyclo[2,2,1]heptane and 3,7-diazabicyclo[3,3,0]octane, wherein said heterocyclic ring is optionally substituted with independently one or more R6;
R6 is C1-C6alkyl optionally substituted with independently one or more halogen, OH, ONO, ONO2, C1-C3alkoxy, C1-C3haloalkoxy, COOR7, NR8R9, C═NR10;
R7 is H, or C1-C4alkyl optionally substituted with F, OH, ONO, ONO2, NR8R9;
R8 and R9 are independently H, or C1-C4alkyl optionally substituted with ONO, ONO2;
R10 is C1-C4alkyl optionally substituted with F, ONO, ONO2; C3-C6cycloalkyl,
wherein preferably said compound of formula I is not

### Claim 2 (depends on 1)

The compound according to claim 1, wherein R1 is methyl or ethyl, preferably methyl.

### Claim 3 (depends on 1, 2)

The compound according to claim 1 or claim 2, wherein R2 is C1-C3alkyl or C3-C6cycloalkyl.

### Claim 4 (depends on 1, 2, 3)

The compound according to any one of the claims 1 to 3, wherein R3 is C1-C4alkyl.

### Claim 5 (depends on 1, 2, 3, 4)

The compound according to any one of the claims 1 to 4, wherein R4 and R5 together with the nitrogen atom to which they are attached form a heterocyclic ring, wherein said heterocyclic ring is selected from piperidine, piperazine and homopiperazine, wherein said heterocyclic ring is optionally substituted with independently one or more R6, preferably optionally substituted with independently one or two R6.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The compound according to any one of the claims 1 to 5, wherein R6 is C1-C6alkyl optionally substituted with independently one or more OH, ONO, ONO2, C1-C3alkoxy.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The compound according to any one of claims 1 to 6, wherein said compound of formula I is a compound of formula I*, and wherein said compound of formula II is a compound of formula II*, or independently a pharmaceutically acceptable salt, solvate or hydrate thereof,
wherein R1, R2, and R3 are as defined in any one of the claims 1 to 4; and wherein
X is CR16 or N;
R11, R12, R13, R14 and R15 are independently H, C1-C6alkyl optionally substituted with independently one or more halogen, OH, ONO, ONO2, C1-C3alkoxy, C1-C3haloalkoxy, COOR17, NR18R19, C═NR20;
R16 is H or C1-C6alkyl optionally substituted with independently one or more halogen, OH, ONO, ONO2, C1-C3alkoxy, C1-C3haloalkoxy, COOR17, NR18R19, C═NR20;
R17 is H, or C1-C4alkyl optionally substituted with F, OH, ONO, ONO2;
R18 and R19 are independently H or C1-C4alkyl optionally substituted with ONO, ONO2;
R20 is C1-C4alkyl optionally substituted with F, ONO, ONO2;
wherein at least one of said R11, R12, R13, R14, R15 and R16 comprises independently at least one ONO2 or ONO moiety,
wherein preferably said compound of formula I* is not

### Claim 8 (depends on 7)

The compound according to claim 7, wherein one of said R13 and R14 is H, and the other of said R13 and R14 is H, C1-C6alkyl optionally substituted with independently one or more halogen, OH, ONO, ONO2, C1-C3alkoxy, C1-C3haloalkoxy, COOR17, NR18R19, C═NR20; said R15 is C1-C6alkyl optionally substituted with independently one or more halogen, OH, ONO, ONO2, C1-C3alkoxy, C1-C3haloalkoxy, COOR17, NR18R19, C═NR20; said R16 is H or C1-C6alkyl optionally substituted with independently one or more halogen, OH, ONO, ONO2, C1-C3alkoxy, C1-C3haloalkoxy, COOR17, NR18R19, C═NR20.

### Claim 9 (depends on 7, 8)

The compound according to claim 7 or claim 8, wherein one of said R13 and R14 is H, and the other of said R13 and R14 is H, C1-C6alkyl optionally substituted with independently one or more halogen, OH, ONO, ONO2, C1-C3alkoxy, C1-C3haloalkoxy; said R15 is C1-C6alkyl optionally substituted with independently one or more halogen, OH, ONO, ONO2, C1-C3alkoxy, C1-C3haloalkoxy; said R16 is H or C1-C6alkyl optionally substituted with independently one or more halogen, OH, ONO, ONO2, C1-C3alkoxy, C1-C3haloalkoxy.

### Claim 10 (depends on 7, 8, 9)

The compound according to any one of claims 7 to 9, wherein
one of said R11 and R12 is H, and the other of said R11 and R12 is H, C1-C6alkyl optionally substituted with independently one or more halogen, OH, ONO, ONO2, C1-C3alkoxy, C1-C3haloalkoxy, COOR17, NR18R19, C═NR20;
one of said R13 and R14 is H, and the other of said R13 and R14 is H, C1-C6alkyl optionally substituted with independently one or more halogen, OH, ONO, ONO2, C1-C3alkoxy, C1-C3haloalkoxy, COOR17, NR18R19, C═NR20;
R15 is C1-C6alkyl optionally substituted with independently one or more halogen, OH, ONO, ONO2, C1-C3alkoxy, C1-C3haloalkoxy, COOR17, NR18R19, C═NR20;
R16 is H or C1-C6alkyl optionally substituted with independently one or more halogen, OH, ONO, ONO2, C1-C3alkoxy, C1-C3haloalkoxy, COOR17, NR18R19, C═NR20;
wherein R17 is H, or C1-C4alkyl optionally substituted with OH, ONO, ONO2;
R18 and R19 are each independently H or C1-C4alkyl optionally substituted with ONO, ONO2.

### Claim 11 (depends on 1)

The compound according to claim 1, wherein said compound is selected from
(R)-1-(1-((4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl)sulfonyl)piperidin-4-yl)ethane-1,2-diyl dinitrate (1a);
(S)-1-(1-((4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl)sulfonyl)piperidin-4-yl)ethane-1,2-diyl dinitrate (1b);
(R)-2-(1-((4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl)sulfonyl)piperidin-4-yl)-2-hydroxyethyl nitrate (1c);
(S)-2-(1-((4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl)sulfonyl)piperidin-4-yl)-2-hydroxyethyl nitrate (1d);
3-(1-((4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl)sulfonyl)piperidin-4-yl)-3-hydroxypropyl nitrate Enantiomer A (1e);
3-(1-((4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl)sulfonyl)piperidin-4-yl)-3-hydroxypropyl nitrate Enantiomer B (1f);
3-(1-((4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl)sulfonyl)piperidin-4-yl)-3,5-dihydroxypentyl nitrate (1g);
3-(1-((4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl)sulfonyl)piperidin-4-yl)-3-hydroxypentane-1,5-diyl dinitrate (1h);
2-((1-((4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl)sulfonyl)piperidin-4-yl)(hydroxy)methyl)propane-1,3-diyl dinitrate (1i);
1-(1-((4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl)sulfonyl)piperidin-4-yl)-2-hydroxyethyl nitrate Enantiomer A (1k);
1-(1-((4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl)sulfonyl)piperidin-4-yl)-2-hydroxyethyl nitrate Enantiomer B (1l);
(R)-1-(1-((4-ethoxy-3-(5-methyl-4-oxo-7-propyl-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)phenyl)sulfonyl)piperidin-4-yl)ethane-1,2-diyl dinitrate (2a);
(S)-1-(1-((4-ethoxy-3-(5-methyl-4-oxo-7-propyl-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)phenyl)sulfonyl)piperidin-4-yl)ethane-1,2-diyl dinitrate (2b);
(R)-2-(1-((4-ethoxy-3-(5-methyl-4-oxo-7-propyl-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)phenyl)sulfonyl)piperidin-4-yl)-2-hydroxyethyl nitrate (2c);
(S)-2-(1-((4-ethoxy-3-(5-methyl-4-oxo-7-propyl-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)phenyl)sulfonyl)piperidin-4-yl)-2-hydroxyethyl nitrate (2d);
3-(1-((4-ethoxy-3-(5-methyl-4-oxo-7-propyl-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)phenyl)sulfonyl)piperidin-4-yl)-3-hydroxypropyl nitrate Enantiomer A (2e);
3-(1-((4-ethoxy-3-(5-methyl-4-oxo-7-propyl-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)phenyl)sulfonyl)piperidin-4-yl)-3-hydroxypropyl nitrate Enantiomer B (2f);
3-(1-((4-ethoxy-3-(5-methyl-4-oxo-7-propyl-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)phenyl)sulfonyl)piperidin-4-yl)-3,5-dihydroxypentyl nitrate (2g);
3-(1-((4-ethoxy-3-(5-methyl-4-oxo-7-propyl-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)phenyl)sulfonyl)piperidin-4-yl)-3-hydroxypentane-1,5-diyl dinitrate (2h);
2-((1-((4-ethoxy-3-(5-methyl-4-oxo-7-propyl-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)phenyl)sulfonyl)piperidin-4-yl)(hydroxy)methyl)propane-1,3-diyl dinitrate (2i);
1-(1-((4-ethoxy-3-(5-methyl-4-oxo-7-propyl-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)phenyl)sulfonyl)piperidin-4-yl)-2-hydroxyethyl nitrate Enantiomer A (2k);
1-(1-((4-ethoxy-3-(5-methyl-4-oxo-7-propyl-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)phenyl)sulfonyl)piperidin-4-yl)-2-hydroxyethyl nitrate Enantiomer B (2l);
2-((1-((4-ethoxy-3-(5-methyl-4-oxo-7-propyl-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)phenyl)sulfonyl)piperidin-4-yl)methyl)propane-1,3-diyl dinitrate (2m);
3-(1-((4-ethoxy-3-(5-methyl-4-oxo-7-propyl-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)phenyl)sulfonyl)piperidin-4-yl)-2-(hydroxymethyl)propyl nitrate (2n);
2-((1-((4-ethoxy-3-(5-methyl-4-oxo-7-propyl-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)phenyl)sulfonyl)piperidin-4-yl)methyl)-2-methylpropane-1,3-diyl dinitrate (2o);
3-(1-((4-ethoxy-3-(5-methyl-4-oxo-7-propyl-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)phenyl)sulfonyl)piperidin-4-yl)-2-(hydroxymethyl)-2-methylpropyl nitrate (2p).

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A pharmaceutical composition comprising at least one of the compounds of formula I or formula II of any one of the claims 1 to 11, or a pharmaceutically acceptable salt, solvate or hydrate thereof, and a pharmaceutically acceptable excipient, adjuvant, or carrier, and wherein preferably said pharmaceutical composition further comprises at least one sGC stimulator, wherein further preferably said sGC stimulator is selected from the group consisting of riociguat, vericiguat, praliciguat and olinciguat.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The compound of formula I or formula II of any one of the claims 1 to 11, or the pharmaceutical composition of claim 12, for use in a method of treating or preventing a disease alleviated by inhibition of PDE5 in a human or in a non-human mammal, preferably in a human, wherein preferably said disease is selected from wound healing, chronic wound healing, diabetic foot, diabetic foot ulcer, leg ulcer, Raynaud's disease, male erectile dysfunction, priapism, female sexual dysfunction, hair loss, skin aging, vascular aging, pulmonary artery hypertension; livedoid vasculopathy, thromboangitis obliterans, chronic anal fissure, skin fibrosis, stable, unstable and variant (Prinzmetal) angina; hypertension, pulmonary hypertension, chronic obstructive pulmonary disease, congestive heart failure, renal failure, atherosclerosis, conditions of reduced blood vessel patency, peripheral vascular disease, vascular disorders, systemic sclerosis (SSc), scleroderma, morphea, achalasia, sickle cell disease (SCD), diabetic nephropathy, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, diabetic neuropathy, Idiopathic pulmonary fibrosis (IPF), peyronic's disease, glaucoma, diabetic retinopathy, age dependent macular degeneration, Retinopathia pigmentosa, or a disease characterized by disorders of gut motility like irritable bowel syndrome, liver fibrosis, Alzheimer's disease, chronic heart failure, and cancer, preferably breast, gastrointestinal, lung, skin, prostate, pancreatic, colon, rectal cancer.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The compound of formula I or formula II of any one of the claims 1 to 11 or the pharmaceutical composition of claim 12, for use in a method of treating or preventing a disease in a human or in a non-human mammal, preferably in a human, wherein said disease is selected from wound healing, chronic wound healing, diabetic foot, diabetic foot ulcer, leg ulcer, Raynaud's disease, male erectile dysfunction, priapism, female sexual dysfunction, hair loss, skin aging, vascular aging, pulmonary artery hypertension; livedoid vasculopathy, thromboangitis obliterans, chronic anal fissure, skin fibrosis, stable, unstable and variant (Prinzmetal) angina; hypertension, pulmonary hypertension, chronic obstructive pulmonary disease, congestive heart failure, renal failure, atherosclerosis, conditions of reduced blood vessel patency, peripheral vascular disease, vascular disorders, systemic sclerosis (SSc), scleroderma, morphea, achalasia, sickle cell disease (SCD), diabetic nephropathy, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, diabetic neuropathy, Idiopathic pulmonary fibrosis (IPF), peyronic's disease, glaucoma, diabetic retinopathy, Retinopathia pigmentosa, age dependent macular degeneration or a disease characterized by disorders of gut motility like irritable bowel syndrome, liver fibrosis, Alzheimer's disease, chronic heart failure, and cancer, preferably breast, gastrointestinal, lung, skin, prostate, pancreatic, colon, rectal cancer, wherein preferably said disease is selected from wound healing, chronic wound healing, diabetic foot, diabetic foot ulcer, leg ulcer, diabetic neuropathy, peripheral vascular disease, vascular disorders such as Raynaud's disease, livedoid vasculopathy, thromboangitis obliterans, chronic anal fissure, skin fibrosis, skin aging, systemic sclerosis (SSc), scleroderma, pulmonary artery hypertension (PAH), chronic thromboembolic pulmonary hypertension, diabetic retinopathy, Retinopathia pigmentosa, age dependent macular degeneration, male erectile dysfunction, priapism, female sexual dysfunction and colorectal cancer, and wherein again further preferably said disease is selected from pulmonary artery hypertension (PAH), chronic thromboembolic pulmonary hypertension, diabetic retinopathy, Retinopathia pigmentosa, age dependent macular degeneration, scleroderma, male erectile dysfunction, skin aging, priapism and female sexual dysfunction, livedoid vasculopathy, thromboangitis obliterans, chronic anal fissure, skin fibrosis, wound healing, chronic wound healing, diabetic foot, diabetic foot ulcer, leg ulcer, diabetic neuropathy and pressure ulcer.

### Claim 15 (depends on 13, 14)

The compound of formula I or formula II for use, or the pharmaceutical composition for use of claim 13 or claim 14, wherein said compound or said pharmaceutical composition is used in combination with at least one sGC stimulator, and wherein preferably said sGC stimulator is selected from the group consisting of riociguat, vericiguat, praliciguat and olinciguat.
